Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 243185, 12 pages
http://dx.doi.org/10.1155/2014/243185
Research Article

H-CRRETAWAC-OH, a Lead Structure for the Development of Radiotracer Targeting Integrin α5β1?

1Department of Nuclear Medicine, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria
2Department of Nuclear Medicine, Molecular Imaging and Radiochemistry, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schwabachanlage 6, 91054 Erlangen, Germany
3Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Schuhstraße 19, 91052 Erlangen, Germany
4Department of Urology, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria

Received 25 April 2014; Accepted 24 May 2014; Published 13 October 2014

Academic Editor: Patrick Riss

Copyright © 2014 Roland Haubner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Welti, S. Loges, S. Dimmeler, and P. Carmeliet, “Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer,” The Journal of Clinical Investigation, vol. 123, no. 8, pp. 3190–3200, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Petrillo, G. Scambia, and G. Ferrandina, “Novel targets for VEGF-independent anti-angiogenic drugs,” Expert Opinion on Investigational Drugs, vol. 21, no. 4, pp. 451–472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Seystahl and M. Weller, “Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?” Expert Opinion on Investigational Drugs, vol. 21, no. 5, pp. 605–617, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Iagaru and S. S. Gambhir, “Imaging tumor angiogenesis: the road to clinical utility,” American Journal of Roentgenology, vol. 201, no. 2, pp. W183–W191, 2013. View at Google Scholar
  5. R. Haubner, A. J. Beer, H. Wang, and X. Chen, “Positron emission tomography tracers for imaging angiogenesis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, supplement 1, pp. S86–S103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Haubner, D. Finsinger, and H. Kessler, “Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy,” Angewandte Chemie—International Edition, vol. 36, no. 13-14, pp. 1374–1389, 1997. View at Google Scholar · View at Scopus
  7. F. C. Gaertner, H. Kessler, H.-J. Wester, M. Schwaiger, and A. J. Beer, “Radiolabelled RGD peptides for imaging and therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, supplement 1, pp. S126–S138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Garmy-Susini and J. A. Varner, “Roles of integrins in tumor angiogenesis and lymphangiogenesis,” Lymphatic Research and Biology, vol. 6, no. 3-4, pp. 155–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. G. H. Mahabeleshwar, W. Feng, D. R. Phillips, and T. V. Byzova, “Integrin signaling is critical for pathological angiogenesis,” The Journal of Experimental Medicine, vol. 203, no. 11, pp. 2495–2507, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. K. L. Goh, J. T. Yang, and R. O. Hynes, “Mesodermal defects and cranial neural crest apoptosis in α5 integrin-null embryos,” Development, vol. 124, no. 21, pp. 4309–4319, 1997. View at Google Scholar · View at Scopus
  11. S. Kim, K. Bell, S. A. Mousa, and J. A. Varner, “Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin,” American Journal of Pathology, vol. 156, no. 4, pp. 1345–1362, 2000. View at Google Scholar · View at Scopus
  12. N. J. Boudreau and J. A. Varner, “The homeobox transcription factor Hox D3 promotes integrin α5β1 expression and function during angiogenesis,” The Journal of Biological Chemistry, vol. 279, no. 6, pp. 4862–4868, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. D. Heckmann, A. Meyer, B. Laufer, G. Zahn, R. Stragies, and H. Kessler, “Rational design of highly active and selective ligands for the α5β1 integrin receptor,” ChemBioChem, vol. 9, no. 9, pp. 1397–1407, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Neubauer, F. Rechenmacher, A. J. Beer et al., “Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3,” Angewandte Chemie—International Edition, vol. 52, no. 44, pp. 11656–11659, 2013. View at Google Scholar
  15. E. Koivunen, B. Wang, and E. Ruoslahti, “Isolation of a highly specific ligand for the α5β1 integrin from a phage display library,” Journal of Cell Biology, vol. 124, no. 3, pp. 373–380, 1994. View at Google Scholar · View at Scopus
  16. E. D. Bergmann and I. Blank, “Studies on organic fluorine compounds. Part I. Some esters of monofluoroacetic acid and related compounds,” Journal of the Chemical Society, vol. 75, pp. 3786–3788, 1953. View at Google Scholar · View at Scopus
  17. R. Haubner, B. Kuhnast, C. Mang et al., “[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates,” Bioconjugate Chemistry, vol. 15, no. 1, pp. 61–69, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Schottelius, J. C. Reubi, V. Eltschinger, M. Schwaiger, and H.-J. Wester, “N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo,” Journal of Medicinal Chemistry, vol. 48, no. 8, pp. 2778–2789, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Guhlke, H. H. Coenen, and G. Stöcklin, “Fluoroacylation agents based on small n.c.a. [18F]fluorocarboxylic acids,” Applied Radiation and Isotopes, vol. 45, no. 6, pp. 715–727, 1994. View at Google Scholar · View at Scopus
  20. O. Prante, J. Einsiedel, R. Haubner et al., “3,4,6-Tri-O-acetyl-2-deoxy-2-[18F]fluoroglucopyranosyl phenylthiosulfonate: a thiol-reactive agent for the chemoselective 18F-glycosylation of peptides,” Bioconjugate Chemistry, vol. 18, no. 1, pp. 254–262, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Haubner, S. Maschauer, and O. Prante, “PET-radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments,” BioMed Research International, vol. 2014, Article ID 871609, 2014. View at Publisher · View at Google Scholar
  22. B. Felding-Habermann, B. M. Mueller, C. A. Romerdahl, and D. A. Cheresh, “Involvement of integrin αv gene expression in human melanoma tumorigenicity,” The Journal of Clinical Investigation, vol. 89, no. 6, pp. 2018–2022, 1992. View at Google Scholar · View at Scopus
  23. D. L. Livant, R. K. Brabec, K. J. Pienta et al., “Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma,” Cancer Research, vol. 60, no. 2, pp. 309–320, 2000. View at Google Scholar · View at Scopus